Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, Open Label, Single Arm, Prospective, Phase IV Study to Evaluate the Safety and Efficacy of MyHep AllTM (sofosbuvir/ velpatasvir, Fixed Dose Combination) in Adult Indian Patients who have Chronic Hepatitis C Virus (HCV) Infection - NIL

Trial Profile

Multicenter, Open Label, Single Arm, Prospective, Phase IV Study to Evaluate the Safety and Efficacy of MyHep AllTM (sofosbuvir/ velpatasvir, Fixed Dose Combination) in Adult Indian Patients who have Chronic Hepatitis C Virus (HCV) Infection - NIL

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 24 Nov 2018

At a glance

  • Drugs Sofosbuvir/velpatasvir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions
  • Sponsors Mylan Laboratories Limited
  • Most Recent Events

    • 13 Nov 2018 New trial record
    • 12 Nov 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top